|Hikma Pharmaceuticals PLC -- UK Stock|| |
GBp 1,102 7.50 0.68%
Sr. Corporate VP of Technical Affairs
Dr. Ibrahim Jalal is Senior Corporationrationrate Vice President Technical Affairs of Hikma Pharmaceuticals Plc. Ibrahim joined Hikma as Technical Director and has held a variety of roles including Corporationrationrate Technical Vice President for Compliance and Senior Corporationrationrate Vice President for RD. He has played a leading role in Hikma securing FDA approval for its manufacturing units. Ibrahim holds a PhD in Pharmacy from the University of WisconsinMadison.
VP Since 2008 Ph.D
44 20 7399 2760 http://www.hikma.com
The company has return on total asset (ROA)
of (12.05) %
which means that it has lost $12.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (42.6) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 776 M in total debt with debt to equity ratio (D/E) of 50.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Hikma Pharmaceuticals PLC has Current Ratio of 1.94 which is within standard range for the sector.
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Pharmaceuticals And Biosciences classification in UK and traded on London Stock Exchange exchange.Hikma Pharmaceuticals PLC (HIK) is traded on London Stock Exchange in UK. It is located in 1 New Burlington Place and employs 7,189 people.